This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
NEW ORLEANS — A new medicine represents a dramatic advance for patients with a rare condition called pulmonary arterial hypertension — and a return to heart disease for Merck, which long had a legendary presence in cardiology. Continue to STAT+ to read the full story…
Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. . The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk patients.
Published in npj Regenerative Medicine, the study reveals a novel approach to promoting cardiomyocyte proliferation. DeBakey Department of Surgery at Baylor College of Medicine, the QIMR Berghofer Medical Research Institute in Brisbane, Australia, and collaborating institutions. The researchers are from the Michael E.
It can be used as a monotherapy or along with cholesterol-lowering medicines. Participants treated with LODOCO had a 31% reduction in the overall risk of cardiovascular death, spontaneous myocardial infarction or ischaemic stroke when added to statins and other cardiology prevention therapies, compared to those treated with placebo.
Fonarow is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA, director of the Ahmanson-UCLA Cardiomyopathy Center, and codirector of the UCLA Preventative Cardiology Program. .” The Grand Rounds session will be held on Friday, July 26, 2024, at 1:00 pm eastern. Join the online meeting.
Technological advancements have fostered novel drugs and improved precision medicine, suggesting an increased trend of R&D in this direction. We support efficacy markers, safety biomarkers, diagnostic biomarkers, and pharmacodynamic (PD) markers, addressing diverse therapeutic areas such as neurology, oncology, immunology, and cardiology.
Fortin, MD, Distinguished Professor of Medicine and a professor of nursing, and Dr. Pagidipati is an associate professor of medicine—both at Duke University. Neha Pagidipati In this Friday’s PCT Grand Rounds, Christopher Granger and Neha Pagidipati of Duke University will present “Lessons From the COORDINATE-Diabetes Trial.”
An automated system that flags which patients could most benefit from an underused yet life-saving cardiology drug more than doubled new prescriptions, according to a pilot program test by researchers at NYU Grossman School of Medicine.
Stone is an Interventional Cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY.
Cardiology is one of the least diverse of the physician specialties, which hampers innovation and excellence (Boston)–Despite working for more than two decades to address underrepresentation of women in cardiology, disparities among cardiovascular professionals continue to exist.
“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. An Internal Medicine Specialist since 2000, Dr. Schenkenberger has practiced at her own clinic since 2002. The post PI Savors Opportunity to Advance Medicine appeared first on Velocity Clinical Research.
Women and those who qualified in medicine outside the UK are most likely to report being subjected to this behaviour, the responses show. One in 10 junior doctors training to be cardiologists in the UK, say they have been bullied, reveal the results of a survey published online in the journal Heart. Bullying of junior doctors […].
Diversity in clinical trials is important for generalizability of results, to provide equal opportunities, practice precision medicine, tailor practical guidelines, improve public health outcomes, detect potential differences in safety and efficacy, and to address health disparities. We have to change how we are practicing.
. – Published monthly, the journal CHEST® features peer-reviewed, cutting-edge original research in chest medicine: Pulmonary, critical care, sleep medicine and related disciplines.
Levels of triglycerides are routinely measured as part of a preventive cardiology work-up and lowering triglycerides with several classes of drugs is common medical practice.
This cohort study evaluates marketing payments from pharmaceutical and medical device manufacturers to physician trainees before and after fellowship graduation.
Published in The Journal of Nuclear Medicine, this research is among the first of its kind to identify the prevalence and outcomes of cardiac amyloidosis among the general population.
Philadelphia, April 29, 2022 – Cardiovascular medicine is ranked among the lowest in terms of female representation in the United States, and cardiac electrophysiology is a predominantly male field.
Study Title: “Association of Blood Viscosity with Mortality among Patients Hospitalized with COVID-19” Journal: Journal of the American College of Cardiology – *Embargoed until July 18, 2 pm EDT Author: Robert Rosenson, MD, Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai and Director of Cardiometabolic (..)
. – UMass Lowell students testing a new device that could transform the way heart-rate data is collected have won praise for their work from the American College of Sports Medicine. A portable sensor that collects heart-rate data shows promise for its accuracy and […].
A Marketing Authorization Application has been submitted to the European Medicines Agency (EMA), with a decision anticipated in 2025. BridgeBio is also working to address gaps in ATTR-CM diagnosis through its TRACE-AI Network Study , a collaboration with the Cardiovascular Data Science Lab (CarDS Lab) at the Yale School of Medicine.
The six newly acquired medicines join Entadfi (finasteride and tadalafil) in Blue Water’s portfolio. Blue Water Biotech has expanded its commercial portfolio with the purchase agreement of six assets from WraSer. The agreement includes an $8.5m cash payment and the offering of one million restricted shares.
For instance, in the LIBerate-HeFH trial in patients with HeFH, the treatment led to mean placebo-adjusted LDL-C reductions of 65% at 24 weeks, with approximately 68% of patients achieving LDL-C reductions of 50% or more, meeting European Society of Cardiology guideline-recommended targets.
The research is presented at ESC Preventive Cardiology 2021, an online scientific congress of the European Society of Cardiology (ESC).1 Sophia Antipolis – 15 April 2021: An observational study in nearly 20,000 individuals has found that greater intake of red and processed meat is associated with worse heart function.
Smidt Heart Institute Chair of Cardiology presents new findings at American Heart Association Scientific Sessions Credit: Photo by Cedars-Sinai LOS ANGELES (Nov.
This cross-sectional study compares 10-year atherosclerotic cardiovascular disease risk and recommendations for primary prevention statin therapy between the 2023 American Heart Association (AHA) Predicting Risk of Cardiovascular Disease (CVD) Events (PREVENT) equations and the 2013 AHA/American College of Cardiology pooled cohort equations.
He serves as director of Atlantic Health System Sports Cardiology and director of the Chanin T. Dr. Martinez also serves as a cardiology consultant for elite and professional athletes, including acting as the League cardiologist for Major League Soccer, team cardiologist for the New York Jets and cardiac consultant for the NFL and NHL.
Sophia Antipolis – 29 June 2021: Heart attacks during the COVID-19 pandemic were more likely to result in heart failure compared with heart attacks one year earlier, according to research presented today at Heart Failure 2021, an online scientific congress of the European Society of Cardiology (ESC).1
Distinguished Professor of Medicine Professor of Nursing Duke University Neha J. This was a cluster-randomized trial of 42 cardiology clinics across the U.S., The cardiology clinics were randomized to one of two groups. Speaker Christopher B. Granger, MD Donald F. Fortin, M.D.
In a study led by Dr. Han Xiao (Department of cardiology and institute of vascular medicine, Peking university third hospital), researchers found that rapid over-activation of ?-adrenergic adrenergic receptors (?-AR) AR) following acute stress initiates cardiac inflammation and injury.
Nudges and other behavioral interventions are prevalent in industries like business and entertainment, but there is an opportunity for nudges in medicine and health care delivery. Launched in 2016, the Penn Medicine Nudge Unit is the world’s first behavioral design team embedded within a health system.
Professor in Translational Cardiology and Pragmatic Randomized Trials. Head of Center for Translational Cardiology and Pragmatic Randomized Trials. Department of Cardiology. You can always use the system to identify potential candidates and then guide them to the local cardiology, kidney department.
The research is presented at ESC Preventive Cardiology 2021, an […]. But a large study today reveals that in people with these conditions, increasing activity levels is associated with a reduced likelihood of heart events and mortality.
Sophia Antipolis, 10 June 2021: High blood pressure, smoking, obesity, heart disease and diabetes are associated with worse outcomes in patients with COVID-19, according to a study published today in European Heart Journal – Quality of Care and Clinical Outcomes, a journal of the European Society of Cardiology (ESC).1
Patients receiving an implantable cardioverter defibrillator (ICD) should be regularly screened for anxiety and depression, according to research presented at EHRA 2021, an online scientific congress of the European Society of Cardiology (ESC).1 For others […].
Using machine learning and clinical data from electronic health records, researchers at the Icahn School of Medicine at Mount Sinai in New York constructed an in silico, or computer-derived, marker for coronary artery disease (CAD) to better measure clinically important characterizations of the disease.
11-12 online The cutting edge of cardiovascular imaging: that’s the focus of EACVI – Best of Imaging 2020, a scientific congress of the European Society of Cardiology (ESC). A pioneering event covering the full spectrum of cardiac imaging. Explore the scientific programme.
That’s the finding of a study published on World Cancer Day in European Heart Journal – Acute Cardiovascular Care, a journal of the European Society of Cardiology (ESC).1 Sophia Antipolis, 4 February 2021: Emergency heart attack treatment is effective in patients with cancer, yet many do not receive it.
AHA, ACC issue updated guidance for the evaluation and management of people with HCM The American Heart Association and the American College of Cardiology today released an updated guideline for managing patients with hypertrophic cardiomyopathy (HCM).
Neurimmune has announced that primary results of its phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC), and published in The New England Journal of Medicine.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content